drugset
drugset / Trial / NCT06363006

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

NCT06363006 ↗

Phase 1 Recruiting 40 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma. The main questions it aims to answer are: * Objective response rate (ORR) for evaluation * Disease Control Rate (DCR); Duration of relief (DoR); Progression free survival (PFS); Total survival time (OS); Safety。

Timeline

Start
2024-03-11
Primary completion
2026-01-01
Completion
2027-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cardonilizumab Unknown 6 mg/kg Intravenous
Background Donafenib Small molecule 200 mg Oral
Background Lenvatinib Small molecule 8 mg Oral
Background Lenvatinib Small molecule 12 mg Oral
Background Regorafenib Small molecule 160 mg Oral
Background Sorafenib Small molecule 400 mg Oral

Indications

hepatocellular carcinoma